文献速递乳腺癌

纳武利尤单抗联合贝伐珠单抗及紫杉醇治疗HER2阴性转移性乳腺癌的安全性与疗效:2期试验(WJOG9917B)主要结果与生物标志物数据

Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
PubMed 文献 · Eur J Cancer · 2022-06-18

这项2期多中心单臂研究(NEWBEAT)评估一线纳武利尤单抗+紫杉醇+贝伐珠单抗治疗HER2阴性转移性乳腺癌,入组57例,客观缓解率70%(39/56,95%CI 55.9-81.2%),中位无进展生存期14.0个月,中位总生存期32.5个月,3/4级药物不良反应58%,未发生5级不良事件。

要点

  • 客观缓解率70%(39/56,95%CI 55.9-81.2%),达到主要终点。
  • 激素受体阳性者客观缓解率74%,三阴性乳腺癌者59%。
  • 3/4级药物不良反应发生于33/57例(58%),免疫相关不良事件43/57例(75%)。

核心结论

  • 一线纳武利尤单抗+贝伐珠单抗+紫杉醇在HER2阴性转移性乳腺癌中显示出有前景的疗效和可控的毒性。

研究设计与样本

  • 2期、多中心、单臂研究(NEWBEAT),评估一线纳武利尤单抗+紫杉醇+贝伐珠单抗治疗HER2阴性转移性乳腺癌,不考虑PD-L1表达。
  • 2018年2月至2018年10月入组57例患者。
  • 主要终点为客观缓解率,关键次要终点包括无进展生存期、总生存期和毒性。
  • 生物标志物研究评估肿瘤PD-L1表达和血清VEGF-A水平。

主要发现

  • 客观缓解率70%(39/56,95%CI 55.9-81.2%),达到主要终点。
  • 激素受体阳性乳腺癌患者客观缓解率74%,三阴性乳腺癌患者59%。
  • 中位无进展生存期14.0个月(95%CI 11.0-16.3),中位总生存期32.5个月(95%CI 26.0-不可评估),中位随访29.5个月。
  • 3/4级药物不良反应发生于33/57例(58%),无5级不良事件。
  • 免疫相关不良事件发生于43/57例(75%),其中3/4级8例(14%)。

关键数值与推荐

  • 肿瘤PD-L1表达与三联治疗疗效不相关。
  • 血清VEGF高组与VEGF低组疗效结局相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinical models revealed potential synergistic effects of programmed cell death-1 inhibitors and anti-vascular endothelial growth factor (VEGF) antibodies. Therefore, we investigated the use of nivolumab, bevacizumab, and paclitaxel triple therapy for metastatic breast cancer. METHODS: This phase 2, multicentre, single-arm study (NEWBEAT) investigated the safety and efficacy of first-line nivolumab, paclitaxel, and bevacizumab in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer, regardless of programmed cell death-ligand 1 expression. The primary end-point was objective response rate. Key secondary end-points included progression-free survival, overall survival, and toxicities. A biomarker study evaluated tumour programmed cell death-ligand 1 expression and serum VEGF-A levels. RESULTS: Between February 2018 and October 2018, 57 patients were enrolled. An objective response rate was seen in 39/56 patients (70%, 95% confidence interval [CI]: 55.9-81.2%), meeting the primary end-point. The objective response rate was 74% in patients with hormone receptor-positive breast cancer versus 59% in patients with triple-negative breast cancer. The median progression-free survival and overall survival were 14.0 (95% CI 11.0-16.3) and 32.5 (95% CI 26.0-not evaluable) months, respectively (median follow-up: 29.5 months). Grade 3/4 adverse drug reactions occurred in 33 of 57 patients (58%). There were no grade 5 adverse events. Immune-related adverse events occurred in 43 of 57 patients (75%), with grade 3/4 events in eight patients (14%). Biomarker analysis showed that tumour programmed cell death-ligand 1 expression was not correlated with the efficacy of triple therapy. Efficacy outcomes were similar between the serum VEGF-high and VEGF-low groups. CONCLUSIONS: First-line nivolumab, bevacizumab, and paclitaxel therapy showed promising efficacy and manageable toxicity in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ozaki Y, Tsurutani J, Mukohara T, et al. Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B). Eur J Cancer. 2022. PMID: 35728379. doi:10.1016/j.ejca.2022.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。